scPharmaceuticals to Announce Fourth Quarter and Full-Year 2023 Financial Results on Wednesday, March 13, 2024Management to host conference call and webcast at 4:30 p.m. ETGlobeNewswireMarch 06, 2024BURLINGTON, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, March 13, 2024, to discuss the financial results for the fourth quarter and full-year 2023 and provide a business update.
Participants should dial 1-877-407-9208 (domestic) or 1-201-493-6784 (international) with the conference code 13744172.
To access the new Call me(TM) feature, which avoids having to wait for an operator, click here.
The live webcast and replay of the conference call can be accessed here or under "News & Events" in the Investor Relations section of the Company's website, www.scpharmaceuticals.com.
About scPharmaceuticals scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company's lead programs focus on the subcutaneous, self-administration of IV-strength treatments in heart failure and infectious disease. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit www.scPharmaceuticals.com.
Katherine MirandascPharmaceuticals Inc., 781-301-6869kmiranda@scpharma.com
Investors:PJ KelleherLifeSci Advisors, 617-430-7579pkelleher@lifesciadvisors.com
COMTEX_448860138/2010/2024-03-06T16:01:34
BURLINGTON, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, March 13, 2024, to discuss the financial results for the fourth quarter and full-year 2023 and provide a business update.
Participants should dial 1-877-407-9208 (domestic) or 1-201-493-6784 (international) with the conference code 13744172.
To access the new Call me(TM) feature, which avoids having to wait for an operator, click here.
The live webcast and replay of the conference call can be accessed here or under "News & Events" in the Investor Relations section of the Company's website, www.scpharmaceuticals.com.
About scPharmaceuticals scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company's lead programs focus on the subcutaneous, self-administration of IV-strength treatments in heart failure and infectious disease. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit www.scPharmaceuticals.com.
Katherine MirandascPharmaceuticals Inc., 781-301-6869kmiranda@scpharma.com
Investors:PJ KelleherLifeSci Advisors, 617-430-7579pkelleher@lifesciadvisors.com
COMTEX_448860138/2010/2024-03-06T16:01:34
0.00% $0.00
